ECRONICON OPEN ACCESS

EC PAEDIATRICS
Guest Editorial

Nerve Transmitters and Receptors Associated with Clinical Anxiety

AJ Russo[1]*, Albert Mensah[2] and Judith Bowman[2]

[1]Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA

[2]Mensah Research Institute, Warrenville, Il, USA

***Corresponding Author:** AJ Russo, Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.

Received: September 29, 2025; **Published:** October 01, 2025

Abstract

Anxiety is a multifaceted emotional state associated with various neurophysiological alterations within the brain. Central to these changes are neurotransmitters, particularly serotonin and dopamine, which exert effects across numerous regions, orchestrating anxiety responses. The serotonergic system is widely implicated in the pathophysiology of anxiety disorders, alongside the dopaminergic system, which is recognized for its modulatory role in anxiety and related conditions like depression. Understanding the intricate balance between these systems can pave the way for novel therapeutic approaches for clinical anxiety.

Keywords: *Nerve Transmitters; Anxiety; Serotonergic System; Dopaminergic System*

The serotonergic system, primarily mediated by serotonin (5-HT) neurotransmission, has been identified as critical in anxiety modulation. Research indicates that distinct serotonergic neuron populations within the dorsal raphe nucleus (DRN) exhibit varying influences on anxiety-related behaviors. Some subpopulations facilitate anxiety responses, while others contribute to the inhibition of anxiety-like states [1,2]. A review by Lowry., *et al*. discusses the activation of specific serotonergic neurons in the dorsal raphe following stress or anxiety-provoking stimuli, noting their involvement in recovery from stress-based disorders, thus illustrating a more nuanced role for serotonergic circuits in emotional regulation [3].

The complexity of the serotonergic system is underscored by varied receptor subtypes, such as 5-HT1A and 5-HT2C, which interact symbiotically to produce nuanced effects on mood and behavior. Activation of the 5-HT1A receptors has been linked to anxiolytic effects, while 5-HT2C receptor activation may exacerbate anxiety symptoms [2,4]. This delicate balance emphasizes the necessity for precise pharmacological interventions selectively targeting these receptors for therapeutic advantages in managing anxiety disorders [5].

Moreover, research has identified corticotropin-releasing factor (CRF) as a significant modulator within serotonergic circuits, often categorized under stress-related pathology. CRF influences serotonergic neurons within the DRN, triggering cascades that may exacerbate anxiety symptoms, indicating the critical role of neuroendocrine factors in the regulation of the serotonergic system and their contributions to anxiety disorders [6,7]. The integrated response from these neurotransmitter systems emphasizes the importance of considering neurochemical and hormonal influences when studying anxiety.

In addition to serotonin, dopamine plays a pivotal role in anxiety regulation. Dopamine dysregulation is often correlated with various mood disorders, including anxiety [8,9]. Dopaminergic pathways, primarily those originating from the substantia nigra and ventral tegmental area (VTA), have been implicated in modulating emotional responses. Studies suggest alterations in dopamine signaling may lead to heightened anxiety-like behaviors in animal models, underscoring the neurotransmitter's role in emotional regulation [9,10]. Pharmacological agents modulating dopamine activity have shown promise in alleviating symptoms of anxiety, corroborating the neurotransmitter's involvement in clinical anxiety [8,11].

Complex interactions between serotonergic and dopaminergic systems suggest they do not operate in isolation but instead significantly influence each other's function. For instance, dopaminergic agonists may yield anxiolytic effects in specific contexts, possibly by enhancing serotonergic transmission or by acting directly on stress-related circuits that involve both neurotransmitters [12]. This interconnectedness is crucial when developing therapeutic strategies, as it highlights the potential for combined pharmacological interventions addressing multiple neurotransmitter systems concurrently.

Animal studies have elucidated these interrelations, with findings indicating that stress modeling induces pronounced changes in both serotonergic and dopaminergic systems. Increased expression of tryptophan hydroxylase (TPH2), a key enzyme in serotonin biosynthesis, and alterations in dopamine transporter expression have been documented in models of chronic stress, correlating with increased anxiety-like behaviors [11,12]. These findings contribute to a better understanding of the molecular basis underlying anxiety disorders.

Neuroimaging studies have advanced understandings of these neurotransmitters' roles in clinical anxiety, particularly through analyses of receptor density and regional brain activity correlating with anxiety symptomatology. Increased activity in brain regions projecting from the DRN to forebrain structures has been observed during anxiety-inducing tasks, highlighting the functional relevance of serotonergic systems [13,14]. Techniques such as magnetic resonance imaging and positron emission tomography have identified alterations in local neural networks associated with serotonergic and dopaminergic activation during anxiety states [8,15].

Ultimately, a comprehensive understanding of the intricate neural circuitry involving serotonergic and dopaminergic systems is crucial for the evolution of therapeutic strategies targeting anxiety disorders. Current psychopharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), exemplify the clinical application of serotonergic modulation aimed at alleviating symptoms of anxiety. However, they are not universally effective and often present with side effects, emphasizing the urgent need for targeted research investigating the pathways involved in these neurotransmitter systems [16,17]. Future studies may focus on understanding the signaling dynamics among various receptor subtypes to develop more precise interventions that mitigate anxiety symptoms with enhanced tolerability.

In conclusion, anxiety is mediated by complex interactions of neurotransmitter systems, primarily serotonergic and dopaminergic pathways. Evidence supports that modulation of these systems influences anxiety behaviors, with various receptors within these pathways presenting potential targets for therapeutic intervention. Continued research in this domain will be vital to unraveling the precise mechanisms at play and developing improved, efficacious strategies for managing anxiety disorders.

Bibliography

1. Lin J., *et al*. "Latest updates on the serotonergic system in depression and anxiety". *Frontiers in Synaptic Neuroscience* 15 (2023): 1124112.

2. Hale MW., *et al*. "Stress-related serotonergic systems: implications for symptomatology of anxiety and affective disorders". *Cellular and Molecular Neurobiology* 32.5 (2012): 695-708.

3. Lowry C., *et al*. "Modulation of anxiety circuits by serotonergic systems". *Stress* 8.4 (2005): 233-246.

4. Jain VK., *et al*. "Evaluation of anxiolytic activity of ondansetron in mice models - an animal experimental research". *Journal of Medical Sciences and Health* 8.2 (2022): 106-112.

5. Grundmann O., *et al*. "Anti-anxiety effects of *Apocynum venetum* l. in the elevated plus maze test". *Journal of Ethnopharmacology* 110.3 (2007): 406-411.

6. Fox JH and Lowry CA. "Corticotropin-releasing factor-related peptides, serotonergic systems, and emotional behavior". *Frontiers in Neuroscience* 7 (2013): 169.

7. Donner NC., *et al*. "Crh receptor priming in the bed nucleus of the stria terminalis (bnst) induces tph2 gene expression in the dorsomedial dorsal raphe nucleus and chronic anxiety". *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 96 (2020): 109730.

8. Doruyter A., *et al*. "Nuclear neuroimaging in social anxiety disorder: a review". *Journal of Nuclear Medicine* 59.12 (2018): 1794-1800.

9. Gao L., *et al*. "Structural and functional alterations of substantia nigra and associations with anxiety and depressive symptoms following traumatic brain injury". *Frontiers in Neurology* 13 (2022): 719778.

10. Mata-Bermúdez A., *et al*. "Dysregulation of the dopaminergic system secondary to traumatic brain injury: implications for mood and anxiety disorders". *Frontiers in Neuroscience* 18 (2024): 1447688.

11. Donner N., *et al*. "Two models of inescapable stress increase tph2 mrna expression in the anxiety-related dorsomedial part of the dorsal raphe nucleus". *Neurobiology of Stress* 8 (2018): 68-81.

12. Smagin DA., *et al*. "Chronic lithium treatment affects anxious behaviors and the expression of serotonergic genes in midbrain raphe nuclei of defeated male mice". *Biomedicines* 9.10 (2021): 1293.

13. Hale MW., *et al*. "Exposure to an open-field arena increases c-fos expression in a subpopulation of neurons in the dorsal raphe nucleus, including neurons projecting to the basolateral amygdaloid complex". *Neuroscience* 157.4 (2008): 733-748.

14. Forster GL., *et al*. "Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity". *European Journal of Neuroscience* 28.2 (2008): 299-310.

15. Ratirat Sangpayap., *et al*. "*Thunbergia laurifolia* linn. extract protects ethanol addiction and increases dopamine synthesis". *Tropical Journal of Natural Product Research* 5.1 (2021): 53-61.

16. Theodoridi A., *et al*. "Acute exposure to fluoxetine alters aggressive behavior of zebrafish and expression of genes involved in serotonergic system regulation". *Frontiers in Neuroscience* 11 (2017): 223.

17. Lowry C., *et al*. "Serotonergic systems, anxiety, and affective disorder". *Annals of the New York Academy of Sciences* 1148.1 (2008): 86-94.

Volume 14 Issue 11 November 2025